Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary

François Potus1, Simon Malenfant, Colin Graydon

  • 1Pulmonary Hypertension Research Group, Quebec Heart and Lung Institute Research Center, Laval University, Quebec City, Canada.

Abstract

Insights

Pulmonary arterial hypertension (PAH) causes exercise intolerance due to reduced muscle microcirculation. This study reveals that down-regulated microRNA-126 (miR-126) in skeletal muscle impairs blood vessel growth, contributing to PAH symptoms.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Exercise Physiology

Background:

  • Pulmonary arterial hypertension (PAH) significantly limits exercise capacity.
  • Skeletal muscle alterations and microRNA (miRNA) dysregulation are implicated in PAH pathogenesis.

Purpose of the Study:

  • To investigate the role of miR-126 in skeletal muscle microcirculation and exercise intolerance in PAH patients.
  • To test the hypothesis that reduced miR-126 in peripheral muscles contributes to PAH-related exercise limitations.

Main Methods:

  • Compared exercise capacity and quadriceps muscle microcirculation (CD31+ staining) in PAH patients and controls.
  • Quantified miR-126 expression and analyzed downstream protein targets (SPRED-1, VEGF pathway) in muscle biopsies.
  • Utilized cell culture assays (Matrigel) and animal models (rats) to confirm miR-126 function.

Main Results:

  • PAH patients showed reduced exercise capacity and muscle capillarity, correlating with decreased miR-126 expression.
  • Down-regulated miR-126 led to increased SPRED-1 and impaired VEGF signaling, hindering angiogenesis.
  • Restoring miR-126 improved angiogenic capacity in PAH cells; inhibiting miR-126 mimicked PAH phenotype in healthy cells.

Conclusions:

  • Exercise intolerance in PAH is linked to skeletal muscle microcirculation loss and impaired angiogenesis.
  • Down-regulation of miR-126 is a key mechanism driving these skeletal muscle abnormalities in PAH.

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
656
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
902
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
760
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
611
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
815
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
694